NASDAQ:SBFM Sunshine Biopharma Q4 2025 Earnings Results & Report $2.78 +0.04 (+1.27%) As of 03:16 PM Eastern This is a fair market value price provided by Massive. Learn more. Sunshine Biopharma missed analyst expectations on both earnings and revenue in its Q4 2025 results, released April 3, 2026. The company reported EPS of -$92.00 versus the -$54.00 consensus estimate, while revenue of $8.58 million fell short of the $10 million estimate by $1.42 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateApril 3, 2026TimeDuring Market Hours Sunshine Biopharma EPS ResultsActual EPS-$92.00Consensus EPS -$54.00Beat/MissMissed by -$38.00One Year Ago EPSN/AEPS Beat Rate2 of last 5 quartersSunshine Biopharma Revenue ResultsActual Revenue$8.58 millionExpected Revenue$10 millionBeat/MissMissed by -$1.42 millionYoY Revenue GrowthN/AUpcoming EarningsSunshine Biopharma's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Sunshine Biopharma Q4 2025 Earnings FAQ Did Sunshine Biopharma beat earnings estimates for Q4 2025? Sunshine Biopharma (NASDAQ:SBFM) reported earnings of -$92.00 per share for Q4 2025, missing the consensus estimate of -$54.00. The report was announced on Friday, April 3, 2026. What was Sunshine Biopharma's revenue for Q4 2025? Sunshine Biopharma reported revenue of $8.58 million for Q4 2025, against a consensus estimate of $10 million. When is Sunshine Biopharma's next earnings date? Sunshine Biopharma's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Sunshine Biopharma on the company's earnings history page. Sunshine Biopharma Earnings HeadlinesSunshine Biopharma (SBFM) Set to Post Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comSunshine Biopharma (SBFM) AI Stock AnalysisNovember 3, 2026 | tipranks.comExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.November 10 at 1:00 AM | Porter & Company (Ad)Sunshine Biopharma consensus price target raised 1,900% to $1,142.40November 1, 2026 | msn.comSunshine Biopharma (NASDAQ:SBFM) Stock Rating Upgraded by Wall Street ZenOctober 31, 2026 | americanbankingnews.comSunshine Biopharma Prices $6 Million Public Offering; Stock DownOctober 8, 2026 | rttnews.comSee More Sunshine Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email. Email Address About Sunshine BiopharmaSunshine Biopharma (NASDAQ:SBFM) is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations. The company has been associated with the distribution and commercialization of prescription and over-the-counter products in Canada, including generic medicines and other healthcare products. Sunshine Biopharma is headquartered in Canada and has conducted its pharmaceutical and biotechnology activities primarily through its Canadian operations. The company has identified Steve Slilaty as its chief executive officer and has traded on the Nasdaq Capital Market under the symbol SBFM. Its business combines the development of proprietary oncology candidates with pharmaceutical product commercialization.View Sunshine Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
